Apolipoprotein B-100-targeted negatively charged nanoliposomes for the treatment of dyslipidemia

Sahebkar, Amirhossein; Badiee, Ali; Hatamipour, Mahdi; Ghayour‐Mobarhan, Majid; Jaafari, Mahmoud Reza

doi:10.1016/j.colsurfb.2015.03.012

Cited by 8 publications

(4 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After vacuum and freeze drying, the obtained thin lipid film was hydrated with histidine (10 mM)/sucrose (10%). The resultant multilamellar dispersions were reduced in size using vortexing, sonication with three cycles of high‐pressure homogenization using an EmulsiFlex‐C3 apparatus (Avestin, Ottawa, ON, Canada) (Sahebkar, Badiee, Ghayour‐Mobarhan, Goldouzian, & Jaafari, ; Sahebkar, Badiee, Hatamipour, Ghayour‐Mobarhan, & Jaafari, ). Hydrodynamic diameters of the nanoliposomes and the polydispersity index of the preparation were measured in triplicate using a Dynamic Light Scattering Instrument (Nano‐ZS; Malvern, Worcestershire, UK).…”

Section: Methodsmentioning

confidence: 99%

“…Previous studies in animal models have successfully utilised immunoliposomal drug delivery systems, for example, anti-P selectin antibody-conjugated liposomes containing vascular endothelial growth factor (VEGF) (Scott et al, 2009) and lectin-like oxidised low-density lipoprotein receptor (LOX)-1 (Saito et al, 2011). A recent study suggested that active targeting of nanoliposomes to LDL particles enhances the liposomelipoprotein interaction to promote plasma cholesterol clearance, probably due to the rapid uptake of nanoliposomes by the liver (Sahebkar & Jaafari, 2015). In that study, a single intravenous dose of apoB-targeted anionic nanoliposomes reduced serum levels of LDL-C, apoB, non-HDL-C, total cholesterol (TC), and triglycerides (TG), while elevating the concentration of HDL-C (Sahebkar & Jaafari, 2015).…”

Section: Introductionmentioning

confidence: 99%

“…A recent study suggested that active targeting of nanoliposomes to LDL particles enhances the liposomelipoprotein interaction to promote plasma cholesterol clearance, probably due to the rapid uptake of nanoliposomes by the liver (Sahebkar & Jaafari, 2015). In that study, a single intravenous dose of apoB-targeted anionic nanoliposomes reduced serum levels of LDL-C, apoB, non-HDL-C, total cholesterol (TC), and triglycerides (TG), while elevating the concentration of HDL-C (Sahebkar & Jaafari, 2015). The lipid-lowering effect of the nanoliposomes was found to last for at least 48 hr and could potentially inhibit atherosclerosis progression.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Anionic nanoliposomes reduced atherosclerosis progression in Low Density Lipoprotein Receptor (LDLR) deficient mice fed a high fat diet

Krishna

Moxon

Jose

et al. 2018

Journal Cellular Physiology

Self Cite

View full text Add to dashboard Cite

Atherosclerosis is a systemic disease characterized by the deposition of cholesterol and inflammatory cells within the arterial wall. Removal of cholesterol from the vessel wall may have an impact on the size and composition of atherosclerotic lesions. Anionic phospholipids or liposome vesicles composed of a lipid bilayer such as nanoliposomes have been suggested as treatments for dyslipidemia. In this study, we investigated the effect of anionic nanoliposomes on atherosclerosis in a mouse model. Low-density lipoprotein receptor knockout mice (Ldlr ) were fed with an atherosclerosis promoting high fat and cholesterol (HFC) diet for 12 weeks. Anionic nanoliposomes including hydrogenated soy phosphatidylcholine (HSPC) and distearoyl phosphatidylglycerol (DSPG) (molar ratio: 1:3) were injected intravenously into HFC-fed Ldlr mice once a week for 4 weeks. Mice receiving nanoliposomes had significantly reduced atherosclerosis within the aortic arch as assessed by Sudan IV staining area (p = 0.007), and reduced intima/media ratio (p = 0.030) and greater collagen deposition within atherosclerosis plaques within the brachiocephalic artery (p = 0.007), compared to control mice. Administration of nanoliposomes enhanced markers of reverse cholesterol transport (RCT) and increased markers of plaque stability in HFC-fed Ldlr mice. Reduced cholesterol accumulation was observed in the liver along with the up-regulation of the major genes involved in the efflux of cholesterol such as hepatic ATP-binding cassette transporters (ABC) including Abc-a1, Abc-g1, Abc-g5, and Abc-g8, Scavenger receptor class B, member 1 (Scarb1), and Liver X receptor alpha (Lxr)-α. Lecithin Cholesterol Acyltransferase activity within the plasma was also increased in mice receiving nanoliposomes. Anionic nanoliposome administration reduced atherosclerosis in HFC-fed Ldlr mice by promoting RCT and upregulating the ABC-A1/ABC-G1 pathway.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Anionic nanoliposomes reduced atherosclerosis progression in Low Density Lipoprotein Receptor (LDLR) deficient mice fed a high fat diet

Krishna

Moxon

Jose

et al. 2018

Journal Cellular Physiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…This means that liposomes can take up cholesterol and return it to the liver for reuse or excretion in the bile. Reverse cholesterol transport decreases the availability of cholesterol at the vascular wall and thereby decreases the production of foam cells [79][80][81][82][83]. ABC transporters act as a mediator of the cholesterol efflux pathways and result in antiatherogenic effects.…”

Section: Roles For Liposomes In the Treatment Of Atherosclerosismentioning

confidence: 99%

A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome

Kiaie

Gorabi

Penson

et al. 2020

Drug Discovery Today

Self Cite

View full text Add to dashboard Cite

Highlights  Atherosclerotic cardiovascular disease (ASCVD) is a major cause of mortality and morbidity worldwide.  Improved visualization of early atherosclerosis and better management of residual risk can reduce ASCVD burden.  Recent research has investigated the potential of biomaterials and nanomedicines in meeting this demand.  Liposomes have a wide range of applications in both imaging and treatment of atherosclerosis.  We review the scientific and clinical evidence relating to the use of liposomes in the context of ASCVD. Teaser: This review describes the experimental and clinical evidence for the use of liposomes in the diagnosis and management of atherosclerotic cardiovascular disease. The consequences of atherosclerotic cardiovascular disease (ASCVD) include myocardial infarction, ischemic stroke, and angina pectoris, which are major causes of mortality and morbidity worldwide. Despite current therapeutic strategies to reduce risk, patients still experience the consequences of ASCVD. Consequently, a current goal is to enhance visualization of early atherosclerotic lesions to improve residual ASCVD risk. The uses of liposomes, in the context of ASCVD, can include as contrast agents for imaging techniques, as well as for the delivery of antiatherosclerotic drugs, genes, and cells to established sites of plaque. Additionally, liposomes have a role as vaccine adjuvants against mediators of atherosclerosis. Here. we review the scientific and clinical evidence relating to the use of liposomes in the diagnosis and management of ASCVD.

show abstract

Nanomaterial in Diverse Biological Applications

Sharma

Shrivastava

Bisht

2017

Metabolic Engineering for Bioactive Compounds

View full text Add to dashboard Cite

Apolipoprotein B-100-targeted negatively charged nanoliposomes for the treatment of dyslipidemia

Cited by 8 publications

References 41 publications

Anionic nanoliposomes reduced atherosclerosis progression in Low Density Lipoprotein Receptor (LDLR) deficient mice fed a high fat diet

Anionic nanoliposomes reduced atherosclerosis progression in Low Density Lipoprotein Receptor (LDLR) deficient mice fed a high fat diet

A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome

Nanomaterial in Diverse Biological Applications

Contact Info

Product

Resources

About